Measuring vitamin B-12 bioavailability with [13C]-cyanocobalamin in humans

Abstract

Vitamin B-12deficiency is widespread inmany parts of the world,affecting all age groups and increasing with age.It is primarily due to a low intake of animalsourcefoodsor malabsorption. The measurement of bioavailability of vitamin B-12 is etiologically important in deficiency but is limited due to the use of radioactive isotopes like [57Co]- or [14C]-cyanocobalamin. The aim of this study was to measure the bioavailability of [13C]-cyanocobalamin in humans and to assess the effect of parenteral replenishment of vitamin B-12 on the bioavailability. We synthesized a stable isotope-labeled vitamin B-12, [13C]-cyanocobalamin, using Salmonella enterica by providing [13C2]-ethanolamine as a sole carbon source. After purification and mass spectrometry-based characterization, its oral bioavailability was measured in the fasted state with high and low oral doses, before and after parenteral replenishment of vitamin B-12 stores, fromthe kinetics of itsplasma appearancein a 2-compartment model. [13C]-cyanocobalamin was completely decyanated to [13C]-methylcobalamin describing metabolic utilization, and its plasma appearance showed early and late absorption phases. At a low dose of 2.3µg,themeanbioavailability was 46.2±12.8 (%, mean±SD, n = 11). At a higher dose of 18.3µg, the mean bioavailability was 7.6±1.7 (%, mean±SD, n=4). Parenteral replenishment of the vitaminB-12 store in deficient individuals prior to the measurement resulted in a 1.9-fold increase in bioavailability. VitaminB-12 bioavailability is dose dependent and at a low dose that approximates the normal daily requirement (46%). The stable isotope method described here couldbe used to define the etiology of deficiency and to informthe dietaryrequirement in different physiologic states as well asthe doserequired forsupplementationandfood fortification. This trial was registered at the Clinical Trials Registry of India as CTRI/2018/04/012957.